J Korean Pediatr Soc.  2003 Nov;46(11):1124-1127.

Arthritis in the Subacute Stage of Kawasaki Disease after Responding to Intravenous Immunoglobulin Treatment

Affiliations
  • 1Department of Pediatric, College of Medicine, The Catholic University of Korea, Seoul, Korea. leekyungyil@catholic ac.kr

Abstract

We evaluated the clinical and laboratory characteristics of five children with Kawasaki disease who had showed arthritis after responding to intravenous immunoglobulin(IVIG) treatment. Age distribution was between 13 months and six years of age(mean 3.2+/-1.6 years). There were two males and three females. Arthritis occurred when acute symptoms were subsiding, with the average onset on day 5.8+/-1.8 after final IVIG treatment. Arthritis was pauciarticular in three, and polyarticular in two. Regarding laboratory findings, one child was positive in rhematoid factor and changed to negative after two months. Three patients were examined for HLA B27 and all showed negative results. High dose aspirin(two cases), anti-inflammatory drug(ibprofen, three cases), and corticosteroids(methyprednisolon pulse therapy, one case) were used for this type of arthritis. Symptoms and signs of arthritis in all patients were improved by these therapies. There was no relapse or complications within six months. Arthritis after responding to IVIG therapy was rarely observed in children with Kawasaki disease. This type of arthritis responded well to anti-inflammatory drugs including corticosteroids, and showed no relapses.

Keyword

Kawasaki disease; Arthritis; Intravenous immunoglobulin

MeSH Terms

Adrenal Cortex Hormones
Age Distribution
Arthritis*
Child
Female
Humans
Immunoglobulins*
Immunoglobulins, Intravenous
Male
Mucocutaneous Lymph Node Syndrome*
Recurrence
Adrenal Cortex Hormones
Immunoglobulins
Immunoglobulins, Intravenous
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr